# Single-dose of Nalmefene to Modulate Neural Alcohol Cue Reactivity

> **NCT02372318** · EARLY_PHASE1 · TERMINATED · sponsor: **Central Institute of Mental Health, Mannheim** · enrollment: 23 (actual)

## Conditions studied

- Alcoholism

## Interventions

- **DRUG:** Nalmefene
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02372318
- **Lead sponsor:** Central Institute of Mental Health, Mannheim
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-04
- **Primary completion:** 2016-05
- **Final completion:** 2016-05
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** Anticipated nr of 25 probands was not reached in terms of full data sets (missing data, low fMRI data quality), but time frame for recruitment ended.
- **Last updated:** 2017-07-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02372318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02372318, "Single-dose of Nalmefene to Modulate Neural Alcohol Cue Reactivity". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02372318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*